Yep, FDA can't very well argue with its own analys

Yep, FDA can't very well argue with its own analysis, one may even argue that indeed the FDA position of the efficacy of Actipatch on women may even be a predicate for the pending FDA submission for musculoskeletal pain relief for women. FDA news should be out soon !
$Biel$